{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:02:17Z","timestamp":1790226137630,"version":"4.1.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced endometrial cancer (EC), including primary unresectable stage III\u2013IV, metastatic, and recurrent disease, is an increasing clinical challenge in the Gulf Cooperation Council (GCC). Rising cardiometabolic risk, heterogeneous referral pathways, variable access to molecular diagnostics, and inconsistent uptake of biomarker-driven therapy contribute to variation in care. This consensus aimed to identify GCC-specific unmet needs and develop regionally adapted recommendations for the diagnosis and management of advanced or recurrent EC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A structured, modified Delphi process was conducted with 12 experts from Bahrain, Kuwait, Qatar, and the United Arab Emirates. Candidate statements were developed from a targeted PubMed literature review and evaluated through 2 rounds of anonymous voting using predefined consensus thresholds. A consensus was considered when voting reached a 75%\u201389% agreement, a strong consensus was defined as \u226590% agreement, and no consensus was defined as &amp;lt;75% agreement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Consensus was achieved on 31 statements. The panel identified key regional gaps, including increasing EC burden, limited GCC-specific molecular and real-world data, inconsistent implementation of molecular testing, variable access to immunotherapy and targeted therapies, and delays in referral to specialized centers. GCC experts recommended routine molecular classification at diagnosis, standardized diagnostic work-up and staging aligned with FIGO 2023, multidisciplinary tumor board review before any clinical decision, carboplatin-paclitaxel plus immunotherapy as the preferred first-line standard for eligible patients, biomarker-informed treatment selection in the post-platinum setting, and early integration of supportive and palliative care. Additional priorities included clinician education, registry development, patient-reported outcomes, and implementation tools to improve real-world quality of care. Final recommendations were classified as international guideline-aligned, GCC-specific adaptation, or expert-opinion recommendation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This consensus provides a practical, GCC-adapted framework to support more consistent, biomarker-informed, and multidisciplinary management of advanced or recurrent EC across the region.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1916197","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:34:27Z","timestamp":1790224467000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced endometrial cancer in the gulf cooperation council: a modified-Delphi consensus on unmet needs, molecular testing, and treatment sequencing"],"prefix":"10.3389","volume":"16","author":[{"given":"Hassan","family":"Jaafar","sequence":"first","affiliation":[{"name":"Department of Oncology, Burjeel Medical City","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref","family":"Chehal","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sheikh Shakhbout Medical City","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basel","family":"Altrabulsi","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine Institute, Cleveland Clinic Abu Dhabi","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"El Shorbagy","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sheikh Shakhbout Medical City","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Hamza","sequence":"additional","affiliation":[{"name":"Department of Oncology, Dubai Hospital","place":["Dubai, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathi","family":"Azribi","sequence":"additional","affiliation":[{"name":"Department of Oncology, American Hospital","place":["Dubai, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Elmalik","sequence":"additional","affiliation":[{"name":"National Center for Cancer Care and Research, Department of Oncology, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Alsindi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Salmaniya Medical Complex","place":["Manama, Bahrain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ashour","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kuwait Cancer Control Centre","place":["Farwaniya, Kuwait"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Hammad","family":"Tirmazy","sequence":"additional","affiliation":[{"name":"Department of Oncology, Dubai Hospital","place":["Dubai, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Dawoud","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tawam Hospital","place":["Al Ain, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1835","article-title":"The global incidence, mortality, and burden of uterine cancer in 2019 and correlation with SDI, tobacco, dietary risks, and metabolic risk factors: An ecological study","volume":"7","author":"Mazidimoradi","year":"2024","journal-title":"Health Sci Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1633894","article-title":"Global burden of cancer in women, 1990\u20132021: a systematic analysis from the GBD 2021 study","volume":"15","author":"Mao","year":"2025","journal-title":"Front Oncol"},{"key":"B3","unstructured":"Ferlay\n              J\n            \n            \n              Ervik\n              M\n            \n            \n              Lam\n              F\n            \n            \n              Laversanne\n              M\n            \n            \n              Colombet\n              M\n            \n            \n              Mery\n              L\n            \n          \n          Lyon (FR\n          International Agency for Research on Cancer\n          Global Cancer Observatory: Cancer Today\n          \n          2024"},{"key":"B4","unstructured":"Uterine Cancer \u2014 Cancer Stat Facts"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.12.008","article-title":"Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records","volume":"164","author":"Monk","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.01.007","article-title":"Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment","volume":"164","author":"Leon-Castillo","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Getz","year":"2013","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynecol Obstet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115893","article-title":"Molecular classification of endometrial cancer and its impact on therapy selection","volume":"25","author":"Galant","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.008","article-title":"Immune checkpoint inhibitors in endometrial cancer: A Cinderella story","volume":"35","author":"Colombo","year":"2024","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO\u2013ESTRO\u2013ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.102860","article-title":"Access to molecular classification in endometrial cancer recommended by ESGO\u2013ESTRO\u2013ESP guidelines: multi-national survey in Eastern Europe","volume":"36","author":"Abacjew-Chmylko","year":"2026","journal-title":"Int J Gynecological Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/S44197-024-00241-5","article-title":"The burden cancer-related deaths attributable to high body mass index in a Gulf Cooperation Council: Results from the Global Burden of Disease Study 2019","volume":"14","author":"Ramadan","year":"2024","journal-title":"J Epidemiol Glob Health"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.2007.251","article-title":"Cancer incidence among the Bahraini population: a five-year (1998\u20132002) experience","volume":"27","author":"Alsayyad","year":"2007","journal-title":"Ann Saudi Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5001\/omj.2018.53","article-title":"Diabesity in the Arabian gulf: Challenges and opportunities","volume":"33","author":"Khalil","year":"2018","journal-title":"Oman Med J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/FPUBH.2021.811006\/BIBTEX","article-title":"Prevalence of metabolic syndrome and associated risk factors in the United Arab Emirates: A cross-sectional population-based study","volume":"9","author":"Mahmoud","year":"2022","journal-title":"Front Public Health"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7954-12-18","article-title":"The diabetes-obesity-hypertension nexus in Qatar: Evidence from the world health survey","volume":"12","author":"Ali","year":"2014","journal-title":"Popul Health Metr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-020-00655-9","article-title":"Prevalence and risk factors of diabetes in a large community-based study in the Sultanate of Oman: STEPS survey 2017","volume":"21","author":"Al-Mawali","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"B19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.12965\/jer.1938758.379","article-title":"Prevalence of metabolic syndrome in the Gulf Cooperation Council countries: Meta-analysis of cross-sectional studies","volume":"16","author":"Shin","year":"2020","journal-title":"J Exerc Rehabil"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.26719\/2023.29.12.995","article-title":"Regional expert meeting on policy action for healthy diets, with a focus on the Gulf Cooperation Council countries","volume":"29","year":"2023","journal-title":"East Mediterr Health J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.2023.315","article-title":"Overall and progression-free survival in endometrial carcinoma: A single-center retrospective study of patients treated between 2000-2018","volume":"43","author":"Sait","year":"2023","journal-title":"Ann Saudi Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.18295\/SQUMJ.3.2024.015","article-title":"Clinicopathological features and outcomes of endometrial cancer: A single institution experience","volume":"24","author":"Burney","year":"2024","journal-title":"Sultan Qaboos Univ Med J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7759\/CUREUS.67332","article-title":"Clinicopathological significance of defective DNA mismatch repair in endometrial carcinoma: A single-center study from Bahrain","volume":"16","author":"Hammad","year":"2024","journal-title":"Cureus"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-022-01165-w","article-title":"Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification","volume":"35","author":"Thompson","year":"2022","journal-title":"Mod Pathol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/S40246-025-00896-6","article-title":"Strategic insights into pharmacogenomics coverage: a theory-informed SWOT analysis of UAE insurance stakeholders\u2019 perspectives","volume":"20","author":"Abbas","year":"2025","journal-title":"Hum Genomics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1089\/JWH.2022.0534","article-title":"Endometrial cancer knowledge and guideline-concordant practice patterns among first-line providers","volume":"32","author":"Sage","year":"2023","journal-title":"J Womens Health (Larchmt)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS17132076","article-title":"The impact of treatment delay on endometrial and ovarian cancer patients: A systematic review","volume":"17","author":"Zouzoulas","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2016.00031","article-title":"A delay from diagnosis to treatment is associated with a decreased overall survival for patients with endometrial cancer","volume":"6","author":"Dolly","year":"2016","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-16-7945-2","volume-title":"Cancer in the Arab World","author":"Al-Shamsi","year":"2022"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3915","article-title":"Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: Interim results of the phase I GARNET study","volume":"29","author":"Oaknin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.04.029","article-title":"Uterine serous carcinoma","volume":"162","author":"Bogani","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPEN-2023-072124","article-title":"Diagnostic accuracy of endometrial sampling tests for detecting endometrial cancer: a systematic review and meta-analysis","volume":"13","author":"Sakna","year":"2023","journal-title":"BMJ Open"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.52054\/FVVO.14.2.023","article-title":"Endometrial biopsy under direct hysteroscopic visualisation versus blind endometrial sampling for the diagnosis of endometrial hyperplasia and cancer: Systematic review and meta-analysis","volume":"14","author":"Di Spiezio Sardo","year":"2022","journal-title":"Facts Views Vis Obgyn"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115329","article-title":"Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis","volume":"220","author":"Villacampa","year":"2025","journal-title":"Eur J Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability\u2013high advanced endometrial cancer: Results from the KEYNOTE-158 study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.02.020","article-title":"Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea","volume":"165","author":"Kim","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02975-x","article-title":"Efficacy of trastuzumab deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: Post hoc analysis of DESTINY-PanTumor02","volume":"41","author":"Oaknin","year":"2024","journal-title":"Adv Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02558","article-title":"Trastuzumab deruxtecan for human epidermal growth factor receptor 2\u2013expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): The STATICE trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02767","article-title":"Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): Analysis in patients with advanced endometrial cancer","volume":"42","author":"Santin","year":"2024","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011129.pub2","article-title":"Early palliative care for adults with advanced cancer","volume":"2017","author":"Haun","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7861\/clinmed.2022-0372","article-title":"Mainstreaming of genomics in oncology: a nationwide survey of the genomics training needs of UK oncologists","volume":"23","author":"Tutika","year":"2023","journal-title":"Clin Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"B51","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/CCO.0000000000000916","article-title":"Improved guideline adherence in oncology through clinical decision-support systems: Still hindered by current health IT infrastructures","volume":"35","author":"Voigt","year":"2023","journal-title":"Curr Opin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1916197\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:34:46Z","timestamp":1790224486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1916197\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":51,"alternative-id":["10.3389\/fonc.2026.1916197"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1916197","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1916197"}}